These authors contributed equally to this work.
PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability
Article first published online: 29 JUL 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 2, pages 692–705, August 2013
How to Cite
Liu, Y., Zhang, J.-B., Qin, Y., Wang, W., Wei, L., Teng, Y., Guo, L., Zhang, B., Lin, Z., Liu, J., Ren, Z.-G., Ye, Q.-H. and Xie, Y. (2013), PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology, 58: 692–705. doi: 10.1002/hep.26398
Potential conflict of interest: Nothing to report.
Supported by grants from National Key Project for Infectious Diseases (2012ZX10002-006, 2012ZX10004-503, 2012ZX10002012-003), National Basic Research Program (2009CB521701, 2012CB519002), Natural Science Foundation of China (31071143, 31170148, 30872505, 81071993, 81172275), and Shanghai Municipal R&D Grant (11DZ2291900, GWDTR201216).
- Issue published online: 29 JUL 2013
- Article first published online: 29 JUL 2013
- Accepted manuscript online: 16 MAR 2013 02:16AM EST
- Manuscript Accepted: 10 MAR 2013
- Manuscript Received: 18 JAN 2013
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of death from cancer worldwide. HCC has a very poor prognosis because of tumor invasiveness, frequent intrahepatic spread, and extrahepatic metastasis. The molecular mechanism of HCC invasiveness and metastasis is poorly understood. The homeobox protein PROX1 is required for hepatocyte migration during mouse embryonic liver development. In this study, we show that high PROX1 protein expression in primary HCC tissues is associated with significantly worse survival and early tumor recurrence in postoperative HCC patients. Knockdown of PROX1 expression in HCC cells inhibited cell migration and invasiveness in vitro and HCC metastasis in nude mice while overexpression of PROX1 in HCC cells promoted these processes. PROX1's pro-metastasis activity is most likely attributed to its up-regulation of hypoxia-inducible factor 1α (HIF-1α) transcription and stabilization of HIF-1α protein by recruiting histone deacetylase 1 (HDAC1) to prevent the acetylation of HIF-1α, which subsequently induces an epithelial-mesenchymal transition response in HCC cells. We further demonstrated the prognostic value of using the combination of PROX1 and HDAC1 levels to predict postoperative survival and early recurrence of HCC. Conclusion: PROX1 is a critical factor that promotes HCC metastasis. (Hepatology 2013;58:692-705)
histone deacetylase 1
hypoxia-inducible factor 1
lymph node metastasis
quantitative real-time polymerase chain reaction
time to tumor recurrence
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of death from cancer worldwide. Although successful curative hepatectomy has significantly improved survival, the prognosis of HCC remains poor owing to tumor invasiveness, frequent intrahepatic spread, and extrahepatic metastasis. The molecular mechanism of HCC invasiveness and metastasis is ill-defined and its elucidation is fundamental to the improvement of HCC prognosis and treatment.
Epithelial-mesenchymal transition (EMT) is a process in which epithelial cells lose polarity and cell–cell adhesion, and are converted to a mesenchymal phenotype. The molecular hallmarks during EMT include down-regulation of epithelial markers (e.g., E-cadherin) and up-regulation of mesenchymal markers (e.g., vimentin). EMT has a crucial role in the progression and metastasis of multiple cancers including HCC.[3, 4] EMT is triggered and controlled by signals cancer cells receive from their microenvironment. One of the major EMT triggers in cancers is the signaling through hypoxia-inducible factor 1 (HIF-1), activated via hypoxia-dependent or hypoxia-independent pathways.[5, 6] Enhanced HIF-1 activities have been reported to promote angiogenesis and invasiveness in HCC.[7, 8]
HIF-1 is composed of a hypoxia-inducible α subunit (HIF-1α) and a constitutively expressing β subunit (HIF-1β). HIF-1α is rapidly degraded under normoxic conditions. During this process, HIF-1α is hydroxylated by prolyl hydroxylase domain proteins (PHDs) at two proline residues (P402 and P564) and subsequently interacts with the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). Acetylation at K532 by ARD1 favors the interaction of HIF-1α with VHL and is coordinated with prolyl hydroxylation and ubiquitination, leading to proteasomal degradation of HIF-1α. Under hypoxia conditions, the activities of PHDs are inhibited and HIF-1α acetylation can be prevented by histone deacetylase 1 (HDAC1). Consequently, HIF-1α is stabilized, translocates to the nucleus, heterodimerizes with HIF-1β, and activates the expression of a broad range of genes including essential regulators for EMT.[11, 12]
The homeobox protein PROX1 is crucial for the development of multiple organs and tissues. Gene knockout analysis in mice indicates that PROX1 is required for hepatocyte migration during embryonic liver development. The role of PROX1 in cancer development has been studied in several cancers. A positive correlation is present between PROX1 protein expression and the malignancy grades of gliomas. High PROX1 protein expression is also associated with poor clinical outcomes of colon cancer. PROX1 is thought not to be responsible for the initiation of colon cancer but rather promotes cancer progression from benign to highly dysplastic phenotype. The connection between PROX1 and HCC is rather obscure. Shimoda et al. showed that the PROX1 messenger RNA (mRNA) level was down-regulated in HCC, and patients with high PROX1-expressing tumors had favorable prognosis compared with those with low PROX1 expression, but there was no statistically significant difference in the disease-free survival rates between these two PROX1 expression groups. However, in a later report, variable levels of PROX1 mRNA were observed in HCC tissues. PROX1 protein expression in HCC samples, nevertheless, has not been investigated systematically. Whether PROX1 plays an important role in HCC invasiveness and metastasis remains unclear.
PROX1's activities in promoting hepatocyte migration during liver development and in colon cancer malignant transformation led us to hypothesize that PROX1 might be intimately involved in HCC invasiveness and metastasis. In this study, we discovered that high PROX1 protein expression in primary HCC tissues was associated with significantly worse clinical outcomes. PROX1 promoted HCC cell migration and invasiveness in vitro and HCC metastasis in nude mice. Mechanism studies revealed that PROX1 induced EMT response in HCC cells via up-regulating HIF-1α transcription and HIF-1α protein stability. We have thus identified PROX1 for the first time as a crucial factor that promotes HCC invasiveness and metastasis.
Patients and Methods
Patients and Clinical Samples
Primary HCC samples were obtained from cohort 1 (n = 227, collected between February 2005 to November 2006), cohort 2 (n = 125, collected between February 1999 to December 2003), and cohort 3 (n = 93) patients who had undergone curative hepatectomy at Zhongshan Hospital. Cohort 3 contained 43 patients with lymph node metastasis (LNM) and 50 patients without LNM randomly picked by computer. The study was approved by the Zhongshan Hospital Research Ethics Committee. Follow-up procedures were described previously. Each patient was followed until March 2010, with the longest follow-up up to 72 months in cohort 1 and 126 months in cohort 2. The clinical characteristics of the HCC patients are presented in Supporting Table S1.
Tissue Microarray (TMA) and Immunohistochemistry (IHC)
Preparation of TMA and IHC procedures were performed as described. The antibodies used in IHC are listed in Supporting Table S2. All IHC staining was independently assessed by two experienced pathologists. The staining intensity was graded from 0 to 2 (0, no staining; 1, weak; 2, strong) (Supporting Fig. S1). The staining extent was graded from 0 to 4 based on the percentage of immunoreactive tumor cells (0%, 1%-5%, 6%-25%, 26%-75%, 76%-100%) (Supporting Fig. S2). A score ranging from 0 to 8 was calculated by multiplying the staining extent score with the staining intensity score, resulting in a low (0-4) level or a high (6-8) level for each sample.
Plasmids and Cell Lines
The human HCC cell lines BEL-7402, Huh7, HepG2, QGY7701, QGY7703, SMCC7721, and embryonic kidney cell line HEK293T were obtained from the Cell Bank of Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences. HCC cell line MHCC-97H was established at the Liver Cancer Institute.
PROX1, HIF-1α, HIF-1b, and HDAC1 cDNAs were cloned downstream of Flag or HA tag in pcDNA3 (Invitrogen, Shanghai, China). Lentiviral vectors pLKO.1 TRC (Addgene 10879) and pWPI.1 (Addgene 12254) were used for constructing recombinant lentiviruses. Oligonucleotides encoding hairpin precursors for si259 (5′-TTTCCAGGAGCAACCA TAATT-3′, corresponding to nt259-279 of PROX1 ORF) and si1646 (5′-GGCTCTCCTTGTCGCTCA TAA-3′, corresponding to nt1646-1666 of PROX1 ORF) were used for generating short interference RNA (siRNA) constructs. A scrambled sequence (Scr) was used as a control. Synonymous mutations were introduced into the target sequence of si1646 (5′-GGCTCTCATTATCACTCATAA-3′, mutations underlined) in PROX1 ORF to generate si1646-resistant PROX1. pEGFP-Prox1 was generated by inserting PROX1 cDNA into pEGFP-C2 (ClonTech, Mountain View, CA). pGL2-HIF-1α contained the promoter (−572/+284) of HIF-1α in pGL2-Basic (Promega, Madison, WI). Cell transfection and luciferase reporter assays were performed as described.
Immunoprecipitation and Mass Spectrometry (IP/MS)
The procedures are detailed in the Supporting Methods.
Coimmunoprecipitation (Co-IP) and GST Pulldown
Co-IP, GST pulldown, and western blot were performed as described. Antibodies used in western blot experiments are listed in Supporting Table S2.
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qrtPCR)
The procedures are detailed in the Supporting Methods.
Chromatin Immunoprecipitation (ChIP)
Anti-PROX1 monoclonal antibody (mAb) (Cell Signaling Technology, Danvers, MA) was used to immunoprecipitate sonicated chromatins prepared from Huh7 or MHCC-97H cells. Preimmune IgG was used for specificity control. Immunoprecipitated DNA was quantitated for HIF-1α promoter (Ct[IP]) using qrtPCR (forward, 5′-GGTGAGGCGGGCTT GCGGGAG-3′; reverse, 5′-GAGGAGCTGAGGCAG CGTCAGGG-3′). DNA from 5% input was quantitated for HIF-1α promoter in parallel (Ct[Input]). The relative occupancy was calculated using the equation: 2^(Ct[Input]-Ct[IP]) *100%.
Cell Migration and Invasiveness Assay and 3D Cell Culture
The procedures are detailed in the Supporting Methods.
Nude Mice and Metastasis Assay
Animal experimental protocols were approved by the Animal Ethics Committee of Shanghai Medical College, Fudan University. Eight-week-old nude mice (BALB/c) were randomly divided into groups (six mice/group) before inoculation or injection. Cells were inoculated into the liver parenchyma of nude mice (BEL-7402 derived cells, 2.0 × 106 cells/mouse) or subcutaneously injected into nude mice (MHCC-97H derived cells, 1.0 × 107 cells/mouse). The mice were sacrificed after 8 weeks and the number of metastatic tumors was assessed by double-blinded evaluation.
Statistical analysis was performed with SPSS v. 13.0. Kaplan-Meier analysis was used for survival analysis and the log-rank test was chosen to compare the difference. Pearson χ2 test or Fisher's exact test were employed to compare qualitative variables, while Student t test was used for quantitative variables. A Cox proportional hazards model was adopted for multivariate analysis. Receiver operating characteristic (ROC) curve analysis was applied to assess the predictive values of variables. P < 0.05 was considered statistically significant for all tests.
High PROX1 Protein Expression in Primary HCC Is Associated With Worse Clinical Outcomes
IHC on tissue microarray was performed to measure PROX1 protein levels in primary HCC samples from 227 postoperative HCC patients (cohort 1) whose 5-year follow-up data were available. In all, 196 patients (86.3%) had a history of hepatitis B and 82 (36.1%) patients were HBV e antigen (HBeAg)-positive. Additionally, 185 patients (81.5%) showed liver cirrhosis (Supporting Table S1). Except one sample damaged during array preparation, the rest of the 226 samples were analyzed. PROX1 was observed mainly in the nuclei of tumor cells and absent in most stroma cells (Supporting Fig. S1). All the samples could be stratified into high PROX1 level (PROX1_hi) and low PROX1 level (PROX1_lo) according to IHC staining scores. Patients with a high serum α-fetoprotein (AFP) level, microvascular invasion, and advanced TNM stage appeared to possess high PROX1 levels in primary HCC tissues (Supporting Table S3).
The PROX1_hi group displayed significantly worse overall survival (OS) (median OS: 38.9 months versus >55 months; log-rank = 9.689, P = 0.002) and shortened time to tumor recurrence (TTR) (median TTR: 27.0 months versus >55 months; log-rank = 6.837, P = 0.009) compared to the PROX1_lo group (Fig. 1A). During the 5-year follow-up period, there were 43 deaths out of 80 patients (53.8%) of the PROX1_hi group compared with 52 deaths out of 146 patients (35.6%) of the PROX1_lo group. These observations were further validated in another cohort comprised of 125 postoperative HCC patients (cohort 2) with about 10-year follow-up data (Supporting Table S1). The second analysis confirmed that high PROX1 protein expression in primary HCC tissues was associated with significantly worse OS (P < 0.001) and shortened TTR (P < 0.001) (Fig. 1B).
Two biologically different forms of HCC recurrence have been proposed. Early recurrence, which occurs within 2 years after treatment, mainly results from dissemination of metastatic HCC cells, while late recurrence is usually a result of a multicentric new tumor in liver. Using 2 years as a cutoff value, the PROX1_hi group was shown to display a significantly higher early recurrence rate compared with the PROX1_lo group (P = 0.026 for cohort 1, P < 0.001 for cohort 2) (Fig. 1A,B). No significant difference was observed for late recurrence between the two groups (P = 0.275 for cohort 1, P = 0.093 for cohort 2) (Supporting Fig. S3).
HBeAg positivity, high AFP level, large tumor size, microvascular invasion, multiple tumors, and advanced TNM stage were found associated with worse OS and shortened TTR in univariate analysis (Table 1). To assess the correlation between high PROX1 level and other risk factors, a Cox proportional hazards analysis was performed, which indicated that high PROX1 level is an independent risk factor for worse OS (hazard ratio = 1.931, P = 0.002) and shortened TTR (hazard ratio = 1.602, P = 0.019) (Table 1).
|Overall Survival||Time to Tumor Recurrence|
|Features||Univariate P Value||Hazard Ratio||95% CI||P Value||Univariate P Value||Hazard Ratio||95% CI||P Value|
|Age (≤52 vs. >52 years)||0.594||NA||0.879||NA|
|Gender (female vs. male)||0.386||NA||0.333||NA|
|Hepatitis B history (yes vs. no)||0.580||NA||0.710||NA|
|Hepatitis B e antigen (positive vs. negative)||0.038||NS||0.009||1.627||1.110–2.384||0.013|
|Liver cirrhosis: yes vs. no||0.946||NA||0.825||NA|
|AFP (<400 vs. ≥400 ng/mL)||0.024||NS||0.005||NS|
|Preoperative ALT (≤75 vs. >75 U/L)||0.636||NA||0.507||NA|
|Tumor size (≤5 vs. >5 cm)||<0.001||3.233||2.020–5.176||<0.001||<0.001||2.264||1.491–3.438||<0.001|
|Tumor encapsulation (complete vs. none)||0.469||NA||0.216||NA|
|Microvascular invasion (yes vs. no)||<0.001||NS||0.001||NS|
|Intrahepatic metastasis (yes vs. no)||0.004||NS||0.008||NS|
|TNM stage (IIIa vs. II vs. I)||<0.001||1.656||1.245–2.202||0.001||<0.001||1.489||1.173–2.024||0.004|
|PROX1 level (low vs. high)||0.002||1.931||1.272–2.931||0.002||0.009||1.602||1.082–2.374||0.019|
PROX1 Promotes HCC Cell Migration and Invasiveness
Association of high PROX1 expression in primary HCC samples with early recurrence suggests that PROX1 might play an important role in HCC invasiveness and metastasis. We then examined PROX1 expression in HCC cell lines possessing varying metastatic potentials. PROX1 was readily detected in HepG2, Huh7, and MHCC-97H cell lines which are highly metastatic in nude mice. However, the absence or a very low level of PROX1 was observed in HCC cell lines with a low metastatic potential (BEL-7402, QGY7701, QGY7703, SMCC7721) (Fig. 2A). Huh7, MHCC-97H, and BEL-7402 were used in the following investigations.
Lentivirus-mediated knockdown and rescue of PROX1 expression in the highly invasive MHCC-97H cells was performed to assess the functional involvement of PROX1 in HCC cell invasiveness in vitro. MHCC-97H-si1646 was established by infection of MHCC-97H cells with a lentivirus expressing si1646 precursor that achieved an 80% reduction in PROX1 expression (Fig. 2B). The control cells were infected with a lentivirus expressing a scrambled siRNA sequence. Compared with the control cells, MHCC-97H-si1646 cells displayed sharp declines in both cell migration and invasiveness, which could be prevented by the expression of si1646-resistant PROX1 (Fig. 2C). On the other hand, exogenous expression of PROX1 in BEL-7402 cells (Fig. 2B) enhanced cell migration and invasiveness (Fig. 2D). These results indicate that PROX1 promotes HCC cell migration and invasiveness in vitro.
PROX1 Interacts With HIF-1α
To explore the mechanism underlying PROX1's promotion of HCC cell invasiveness, IP/MS was conducted to identify key factors associated with PROX1. Flag-PROX1 produced in HEK293T cells was immunoprecipitated by anti-Flag mAb and coprecipitated proteins were visualized by silver staining after electrophoresis and identified by MS. One coprecipitated factor turned out to be HIF-1β (Fig. 3A). The association of PROX1 with HIF-1β was verified in HEK293T and Huh7 cells (Fig. 3B). As HIF-1β is able to heterodimerize with HIF-1α, it can be deduced that PROX1 may be associated with HIF-1α as well. This assumption was confirmed in HEK293T transfected with the expression plasmid for Flag-Prox1 and in Huh7 cells with endogenous proteins (Fig. 3C). Moreover, coexpressed EGFP-PROX1 and HA-HIF-1α were found to colocalize in Huh7 cells (Fig. 3D). Finally, GST-HIF-1α was expressed in Escherichia coli and the full-length PROX1 was produced via in vitro translation. The results of GST pulldown assays indicate that PROX1 directly interacts with HIF-1α (Fig. 3E).
To determine the regions mediating the interaction, several GST-fused HIF-1α fragments were produced (Fig. 3E) and each was tested for interaction with PROX1. The region spanning the residues 1-344 of HIF-1α appeared responsible for the interaction between HIF-1α and PROX1, and the amino-terminal 84 residues containing the basic helix-loop-helix domain might be the main interactive motif (Fig. 3E). Reciprocally, Flag-tagged PROX1 fragments were produced in HEK293T cells (Fig. 3F) and tested for interaction with GST-HIF-1α. The results of GST pulldown assays suggest that the amino-terminal two-thirds (amino acids 1-570) but not the putative DNA binding domain of PROX1 was responsible for the interaction with HIF-1α (Fig. 3F).
PROX1 Up-Regulates HIF-1α Expression and Induces EMT Response in HCC Cells
Next, we wondered whether PROX1 might regulate HIF-1α expression in HCC cells. Western blot analysis showed that HIF-1α expression was reduced by knockdown of PROX1 expression in Huh7 and MHCC-97H cells (Fig. 4A) but increased by overexpression of PROX1 in BEL-7402 and Huh7 cells (Fig. 4B). Meanwhile, the expression of E-cadherin was up-regulated in PROX1-knockdown cells and down-regulated in PROX1-overexpressing cells, which was reversely correlated with the change in the expression of vimentin (Fig. 4A,B). Importantly, exogenous expression of HIF-1α could counteract the effects of knockdown of PROX1 expression in Huh7 cells (Fig. 4C). These results indicate that PROX1 can induce EMT response in HCC cells and HIF-1α is most likely involved in this process.
We further investigated whether knockdown of PROX1 expression in the highly invasive MHCC-97H cells might cause any change in cell morphology and behavior. PROX1-knockdown cells (MHCC-97H-si259, MHCC-97H-si1646) appeared to have more of an epithelial-like morphology than the mesenchymal spindle-like morphology characteristic of MHCC-97H and the control MHCC-97H-Scr cells (Fig. 4D), implying that PROX1 is required for maintenance of the mesenchymal morphology of MHCC-97H cells.
PROX1 Activates HIF-1α Transcription
An increase in HIF-1α expression might result from activated HIF-1α transcription and/or enhanced HIF-1α protein stability. Indeed, HIF-1α mRNA levels were increased in PROX1-overexpressed BEL-7402 and Huh7 cells (Fig. 5A) but reduced in PROX1-knockdown Huh7 and MHCC-97H cells (Fig. 5B). Moreover, luciferase reporter assays indicated that PROX1 can activate HIF-1α promoter (Fig. 5C). Finally, ChIP-qrtPCR assays suggest that endogenous PROX1 is associated with HIF-1α promoter in Huh7 and MHCC-97H cells (Fig. 5D). Together, these results clearly indicate that PROX1 can activate HIF-1α transcription.
PROX1 Inhibits HIF-1α Acetylation
HDAC1 recruited by HIF-1α-associated factors can prevent acetylation of HIF-1α to stabilize HIF-1α. Whether PROX1 employed this strategy was investigated. First, PROX1 was shown to interact with HDAC1 in HEK293T and Huh7 cells (Fig. 6A). Second, coexpressed EGFP-PROX1 and HA-HDAC1 colocalized in Huh7 cells (Fig. 6B). Next, HEK293T cells without endogenous PROX1 expression were cotransfected with PROX1 and Flag-HIF-1α expression constructs. Flag-HIF-1α was pulled down by anti-Flag mAb, followed by detection of HDAC1 and acetylated Flag-HIF-1α. With PROX1 coexpression, much more HDAC1 was coprecipitated with Flag-HIF-1α, while the amount of acetylated Flag-HIF-1α as detected by pan-Acetyl antibody was markedly decreased (Fig. 6C). Furthermore, HDAC1 expression was reduced by knockdown of PROX1 expression in Huh7 and MHCC-97H cells but increased by overexpression of PROX1 in BEL-7402 and Huh7 cells (Fig. 6D). Collectively, these results suggest that PROX1 inhibits HIF-1α acetylation by recruiting HDAC1 and up-regulating HDAC1 expression. However, the possibility that HDAC1 might be recruited by other HIF-1α-associated factors cannot be excluded.
IHC on tissue microarray of primary HCC samples from cohort 1 patients was then performed to assess whether PROX1 and HDAC1 expression was correlated in HCC. A strong positive correlation between PROX1 and HDAC1 levels was observed (r = 0.419, P < 0.001) (Fig. 6E). The patients whose HCC samples showed above-medium levels (scoring >4) of both PROX1 and HDAC1 suffered exacerbated adverse clinical outcomes than the patients with below-medium levels (scoring ≤4) of both PROX1 and HDAC1 (OS P < 0.001, TTR P = 0.003, Supporting Fig. S4). Finally, the combination of PROX1 and HDAC1 levels appeared to have a better prognostic value for OS and early recurrence than PROX1 alone according to the ROC curve analysis (Fig. 6F; Supporting Table S4).
PROX1 Promotes HCC Metastasis in Nude Mice
Metastasis assays by inoculation or injection of HCC cells into nude mice were conducted to investigate whether PROX1 promotes HCC metastasis. First, BEL-7402-Prox1 was established by infection of the low metastatic BEL-7402 with the PROX1-expressing lentivirus. The control BEL-7402-Mock was generated by infection of BEL-7402 with the vector lentivirus. These cells were inoculated into the liver parenchyma of nude mice to create orthotopic xenograft models. After 8 weeks, the BEL-7402-Prox1 group displayed significantly more metastases in mesenteric lymph nodes (mean = 46.0 ± 35.9 per mouse) than the control group (mean = 2.3 ± 4.1 per mouse) (P = 0.014) (Fig. 7A). The number of lung metastatic nodules revealed by hematoxylin and eosin staining was also higher in the BEL-7402-Prox1 group, although the difference did not reach statistical significance (P = 0.135). The BEL-7402-Prox1 group also had larger tumors in liver (P = 0.012) (Fig. 7B). None of the mice in the BEL-7402-Prox1 group survived at day 65 postinoculation, while 50% of the mice in the control group did (P = 0.007) (Fig. 7C). Compared with the tumors of BEL-7402-Mock origin, a reduction in E-cadherin expression and increase in vimentin and HIF-1α expression were observed in the tumors derived from BEL-7402-Prox1 cells, suggesting that PROX1-induced EMT plays a key role in HCC metastasis in this model (Fig. 7D).
Lymph node metastasis (LNM) was reported in about 7% of Chinese HCC cases, correlated with advanced disease and extremely poor survival. We compared PROX1 expression in primary HCC samples between 43 patients with LNM and 50 randomly picked patients without LNM. Thirty (69.8%) out of 43 patients with LNM showed high PROX1 expression in primary HCC tissues in comparison to 22 (44%) out of 50 patients without LNM (P = 0.001) (Fig. 7E).
Lung metastasis frequently occurs in HCC. To further investigate the role of PROX1 in HCC lung metastasis, we used the MHCC-97H cell line, which has a high rate of spontaneous lung metastasis when injected subcutaneously. MHCC-97H-si1646 and MHCC-97H-Scr were respectively established by infection of MHCC-97H cells with the lentivirus expressing si1646 precursor and the lentivirus expressing scrambled siRNA precursor. These cells were subcutaneously injected into nude mice. All the mice in both groups developed tumors. After 8 weeks, five out of six mice in the control group were found to have lung metastases (mean of number of metastatic nodules per lung = 4.7 ± 3.3), while none in the MHCC-97H-si1646 group developed lung metastases (P = 0.015) (Fig. 7F).
Although several genes associated with HCC metastasis have been identified in the past few years,[24, 26-31] the molecular mechanism of HCC invasiveness and metastasis is still not well understood. Much evidence has been presented to indicate that EMT is crucial for cancer invasiveness and metastasis.[3, 4, 32] Nevertheless, a more in-depth understanding of the factors promoting EMT in HCC and HCC metastasis is urgently needed in order to identify specific biomarkers for improving HCC prognosis and treatment. Because of its essential function in promoting hepatocyte migration during mouse embryonic liver development, PROX1's role in HCC invasiveness and metastasis is intriguing but unsolved. In this study, we demonstrated that PROX1 promoted HCC cell migration and invasiveness in vitro and HCC metastasis to lymph nodes and lung in nude mice. The molecular mechanism underlying PROX1's Pro-metastasis activity is most likely attributed to its up-regulation of HIF-1α transcription and HIF-1α protein stability, which consequently induces an EMT response in HCC cells. Accordingly, high PROX1 expression in primary HCC tissues is associated with significantly worse postoperative survival and early tumor recurrence. Collectively, we pinpointed PROX1 for the first time as a critical factor that promotes HCC metastasis.
The role of PROX1 in HCC development was unsolved because previous reports had not investigated the role of PROX1 in HCC metastasis. Dudas et al. analyzed PROX1 mRNA levels in small numbers of normal, cirrhotic, and HCC liver samples using quantitative RT-PCR and northern blot, but no clear correlation with disease was observed. In another earlier work, however, Shimoda et al. also used quantitative RT-PCR to evaluate PROX1 mRNA levels in 52 HCC samples and identified a positive correlation between PROX1 mRNA level and better prognosis. The discrepancy between the latter results and our data reported in this work might be attributed to several factors. First, PROX1 mRNA expression rather than protein expression was examined in the previous report. High PROX1 mRNA expression itself does not necessarily result in high PROX1 protein expression. Second, the differences in HCC patients' background, especially a history of infection with HCC-inducing pathogens, may have a profound influence on HCC development. For example, only one-fourth of the HCC patients in Shimoda et al.'s study had a history of HBV infection. In contrast, more than 70% of Chinese HCC patients are infected with HBV. In our case, the rate of HBV infection is 86.3% for cohort 1 and 84% for cohort 2. There were 31 non-HBV patients in cohort 1, and among them 11 and 20 belong to the high PROX1 level group and low PROX1 level group, respectively. Interestingly, there is no statistical significance for the differences in OS and TTR between these two groups (Supporting Fig. S5). Nevertheless, it is premature to reach a conclusion because the number of non-HBV patients in cohort 1 is rather small. Third, a relatively small number of HCC patients (n = 52) were included in the previous study, although statistical significance was strong (P = 0.014).
PROX1-mediated up-regulation of HIF-1α expression in HCC cells occurs at two levels: the activation of HIF-1α transcription and the stabilization of HIF-1α protein through prevention of HIF-1α acetylating. Although it contains a DNA binding domain located at the carboxyl terminal one-third, PROX1 does not usually regulate transcription by directly binding to target gene promoter DNA. Instead, PROX1 often serves as a coregulator for transcription factors.[22, 33] HIF-1α transcription is activated by nuclear factor kappa B (NF-κB), which is, to date, not known to partner with PROX1. Therefore, how PROX1 activates HIF-1α transcription remains an interesting topic for future study. On the other hand, recruitment of HDAC1 to stabilize HIF-1α has been reported to be employed by metastasis-associated protein 1 (MTA1) in breast cancer cells. Interestingly, MTA1 belongs to a family of proteins associated with tumor metastasis. The similarity between PROX1 and MTA1 in HDAC1 recruitment to stabilize HIF-1α suggests a possible common strategy cancer cells may utilize to achieve metastasis.
Given the extremely poor prognosis of HCC, biomarkers for improving HCC prognosis and intervention are urgently needed. According to our ROC curve analysis, tumor size and TNM stage are the most effective predictors of survival and early recurrence among postoperative HCC patients. The combination of PROX1 and HDAC1 levels appears a potentially useful predictor for survival and early recurrence. Since a high PROX1 level is an independent risk factor for poor OS and shortened TTR (Table 1), we speculate that combining PROX1/HDAC1 levels with tumor size and TNM stage may increase the predictive power. This hypothesis should be tested in a prospective study with postoperative HCC patients. From a therapeutic viewpoint, the concurrent increase in HDAC1 protein expression in HCCs with high PROX1 level suggests that inhibitors of HDAC1 might be potent drugs against HCC metastasis. On the other hand, elucidation of the molecular mechanism leading to high PROX1 expression in certain HCC patients and discovery of the means to suppress PROX1 activity may provide novel therapies for preventing HCC metastasis.
Additional Supporting Information may be found in the online version of this article.
|hep26398-sup-0001-suppfig1.tif||5562K||Supporting Information Figure 1|
|hep26398-sup-0002-suppfig2.tif||3731K||Supporting Information Figure 2|
|hep26398-sup-0003-suppfig3.tif||1200K||Supporting Information Figure 3|
|hep26398-sup-0004-suppfig4.tif||1652K||Supporting Information Figure 4|
|hep26398-sup-0005-suppfig5.tif||1219K||Supporting Information Figure 5|
|hep26398-sup-0006-supptab1.doc||34K||Table S1. Clinicopathologic features of patients from two cohorts|
|hep26398-sup-0007-supptab2.doc||35K||Table S2. Primary antibodies for western blot, immunohistochemistry and co-immunoprecipitation|
|hep26398-sup-0008-supptab3.doc||80K||Table S3. Comparison of clinicopathologic profiles between HCC patients of high PROX1 level and low PROX1 level in cohort 1|
|hep26398-sup-0009-supptab4.doc||39K||Table S4. Prognostic values of variables for overall survival, recurrence and early recurrence|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.